GLP-1s Show Potential in Preventing Subarachnoid Hemorrhage

Recent clinical research published in the journal Stroke suggests that glucagon-like peptide-1 (GLP-1) receptor agonists, already recognized for their potent glycemic and cardioprotective benefits, may offer a significant new shield against subarachnoid hemorrhage.¹

Results of the Cohort Study

This retrospective cohort study, which utilized a global database of over 130 million patients, found that individuals with type 2 diabetes and unruptured intracranial aneurysms who were treated with GLP-1s experienced a 34% reduction in the risk of nontraumatic subarachnoid hemorrhage compared to those receiving other glucose-lowering medications. Furthermore, the study revealed that GLP-1 use was associated with a 37% decrease in all-cause mortality over a 5-year follow-up period.

These findings are particularly relevant for pharmacists, as they suggest that the neuroprotective profile of these medications extends beyond blood sugar control to the stabilization of high-risk vascular structures in the brain.

The urgency of identifying effective preventive therapies is underscored by the well-documented connection between diabetes and stroke, as individuals with diabetes are twice as likely to suffer a stroke as those without the condition. Chronic hyperglycemia leads to the formation of fatty deposits and clots within the blood vessels, often resulting in premature vascular aging and a significantly poorer prognosis following a stroke event.^2,3

Although previous research and cardiovascular outcome trials have firmly established that GLP-1s like dulaglutide and semaglutide reduce the risk of ischemic stroke by approximately 17%, the new data indicates a broader utility in preventing hemorrhagic events by mitigating the risk of aneurysm rupture.^1,3

The mechanisms driving these benefits appear to be multifaceted, involving both direct and indirect neuroprotective pathways. GLP-1s are believed to suppress neuroinflammation and enhance endogenous antioxidant production, which helps limit neuronal damage and attenuate the proinflammatory components of atherosclerosis. Additionally, these agents have been shown to improve blood pressure control, potentially by increasing atrial natriuretic peptide production and by reducing the hemodynamic stress on aneurysm walls that often leads to rupture.^1,2

Role of the Pharmacist

For pharmacists, understanding these mechanisms is key to explaining the long-term value of these medications to patients who may initially focus only on their glucose-lowering or weight loss effects.^1,2

From a clinical pharmacy perspective, the integration of GLP-1s into a patient’s regimen requires careful management of titration and potential drug-drug interactions. To minimize common but transient adverse effects like nausea and vomiting, patients should be started on low doses, such as 0.75 mg weekly for dulaglutide or 0.25 mg weekly for subcutaneous semaglutide, with gradual up-titration every 4 weeks as tolerated.³

Pharmacists play a vital role in polypharmacy oversight by ensuring that dipeptidyl peptidase-4 inhibitors are discontinued when a GLP-1RA is initiated, as these medications work through the same incretin pathway and the combination is redundant. Furthermore, if a patient’s baseline A_1C is below 8%, pharmacists must collaborate with the care team to potentially reduce dosages of sulfonylureas or insulin by approximately 20% to mitigate the risk of hypoglycemia.³

Beyond pharmacotherapy, pharmacists can reinforce foundational stroke prevention strategies, such as maintaining a blood pressure target below 140/90 mm Hg and adhering to a heart-healthy diet rich in fiber. Counseling on smoking cessation is also critical, as smoking significantly increases the risk of heart disease and stroke regardless of a patient's diabetic status.²

As the use of GLP-1s becomes increasingly prevalent in the management of type 2 diabetes, the emerging evidence of their role in mitigating nontraumatic subarachnoid hemorrhage provides a compelling call to action for health care providers to utilize these agents more aggressively in high-risk populations. This evolving therapeutic landscape offers an exciting opportunity for pharmacists to have a meaningful impact on preventing both ischemic and hemorrhagic stroke through expert medication management and patient education.^1,3

REFERENCES

1. Feghali J, Ruchika F, Horowitz MA, et al. Glucagon-Like Peptide-1 Receptor Agonists and Decreased Subarachnoid Hemorrhage Risk in Patients With Intracranial Aneurysm. Stroke. Published online January 6, 2026. doi:10.1161/STROKEAHA.125.053599

2. American Stroke Association. Diabetes and Stroke Prevention. Accessed February 20, 2026. https://www.stroke.org/en/about-stroke/stroke-risk-factors/diabetes-and-stroke-prevention

3. Goldenberg RM, Cheng AYY, Fitzpatrick T, Gilbert JD, Verma S, Hopyan JJ. Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists. Stroke. 2022;53(5):1813-1822. doi:10.1161/STROKEAHA.121.038151